Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canadian experts say no age bar for pre-natal screening:

This article was originally published in Clinica

Executive Summary

Noninvasive prenatal genetic screening (ultrasound, blood testing) should be extended to all Canadian women, regardless of their age, to reduce the number of invasive tests and allow effective prenatal planning and care. This is the primary recommendation by leading physicians in the field, published this month in the Journal of Obstetrics and Gynaecology Canada (JOGC). Testing is currently offered to women over-35 who are at greater risk of giving birth to a child with a condition caused by genetic abnormalities, such as Down's syndrome. Among the other recommendations was that screening programmes should be implemented with resources to support multiple services, including audited screening and diagnostic lab services, ultrasound and high quality diagnostic testing.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT047553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel